Skip to main content
SpringerLink
Log in

Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

A phase I study with recombinant human tumor necrosis factor α (rhuTNF-α; Knoll AG, Ludwigshafen, FRG) in patients with advanced malignant disease was undertaken to evaluate drug toxicity (organ specifity, time course, predictability, reversibility, maximal tolerated dose), effectiveness, antigenicity and pharmacokinetics. TNF was administered as a test dose followed by daily i.v. infusions for 5 days, every 3 weeks (single i.v. infusion lasting 10 min, TNF dissolved in 50 ml 5% human albumin). Dosage was increased in groups of 3 or 4 patients from 0.04 mg/m2 to 0.28 mg/m2. A total of 19 patients with different cancers, including seven large-bowel carcinomas, three chronic myelogenous leukemias, three hypernephromas, two small-cell lung cancers, one malignant melanoma, one malignant lymphoma, one rhabdomyosarcoma and one fibrosarcoma were treated. Major side-effects were chills and fever (maximum 40.4°C, median 38.7°C, 19/19), headache (12/19), nausea and vomiting (12/19) and pronounced (>20%) hypotension (4/19). Acute side-effects could be diminished by paracetamol or indomethacin pretreatment, and with one possible exception no tachyphylaxis to TNF was noted. Mild renal toxicity was seen during TNF treatment. Pharmacokinetic studies showed a serum half-life (t 1/2) ranging from 11 min to 17 min for doses from 0.04 mg/m2 to 0.16 mg/m2 and prolonged clearance with t 1/2 ranging from 54 min to 70 min in the 0.20–0.28 mg/m2 dose range. No objective antitumor effects were observed in this phase I study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, Fiers W (1986) Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 46:3990

    Google Scholar 

  2. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resoption and inhibition of bone formation in vitro by human tumor necrosis factor. Nature 319:516

    Google Scholar 

  3. Beutler B, Cerami A (1987) Cachectin: more than a tumor necrosis factor. N Engl J Med 316:379

    Google Scholar 

  4. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin / tumor necrosis factor protects mice from lethal effects of endotoxin. Science 229:869

    CAS  PubMed  Google Scholar 

  5. Broudy VC, Kaushnansky K, Segal GM, Harlan JM, Adamson JW (1986) Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci USA 83:7467

    Google Scholar 

  6. Carswell EA, Old LA, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666

    CAS  PubMed  Google Scholar 

  7. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes HF, Sherwin SA, Old LJ, Oettgen HF (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5:1942

    Google Scholar 

  8. Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A, Proefrock A (1987) Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20:137

    Google Scholar 

  9. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O'Connor JV (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogene and induces production of interleukin 1. J Exp Med 163:1433

    Google Scholar 

  10. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA (1985) Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82:8667

    Google Scholar 

  11. Gray PW, Aggerwal BB, Benton CV, Bringman TS, Henzel WJ, Jarrett JA, Leung DW, Moffat B, Ng P, Svedersky LP, Palladino MA, Nedwin GE (1984) Cloning and expression of c-DNA for human lymphotoxin, a lymphokine with tumor necrosis activity. Nature 312:721

    Google Scholar 

  12. Haranaka K, Satomi N, Sakurai A (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34:263

    Google Scholar 

  13. Helson L, Green S, Carswell E, Old LJ (1975) Effects of tumor necrosis factor on cultured human melanoma cells. Nature 258:731

    Google Scholar 

  14. Kettelhut IC, Fiers W, Goldberg AL (1987) The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci USA 84:4273

    Google Scholar 

  15. Kimura K, Taguchi T, Urushizaki J, Ohno R, Abe O, Furue H Hattori T, Ichizaki H, Inoguchi K, Majima H, Niitani H, Ota K, Saito T, Suga S, Suzuoki Y, Wakui A, Yamada K, The TNF Cooperative Study Group (1987) Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20:223

    Google Scholar 

  16. Lu L, Welte K, Gabrilove JL, Hangoc C, Bruno E, Hoffman R, Broxmeyer HE (1986) Effects of recombinant human tumor necrosis factor alpha, recombinant human interferon gamma and prostaglandin E on colony formation of human hematopoietic progenitor cells stimulated by natural human pluripotent colony-stimulating factor, pluripoietin alpha and recombinant erythropoietin in serum-free cultures. Cancer Res 46:4357

    Google Scholar 

  17. Marmenout A, Fransen L, Tavernier J, von der Heiden J, Tizard R, Kawashima E, Shaw A, Johnson MJ, Semon D, Müller R, Ruysschaert MR, Van Vliet A, Fiers W (1985) Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor. Eur J Biochem 152:515

    Google Scholar 

  18. Mestan J, Digel W, Mittnacht S, Hillen H, Bloem D, Möller A, Jacobsen H, Kirchner H (1986) Antiviral effects of recombinant tumor necrosis factor in vitro. Nature 323:816

    Google Scholar 

  19. Niederle N, Kloke O, Osieka R, Wandl U, Opalka B, Schmidt CG (1987) Interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Oncol 14, Suppl 2:29

    Google Scholar 

  20. Old LJ (1985) Tumor necrosis factor. Science 230:630–632

    Google Scholar 

  21. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggerwal BB, Goeddel DV (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312:724

    Google Scholar 

  22. Sato N, Goto T, Haranaka K, Satoni N, Nariuchi H, Mano-Hirano Y, Sawasaki Y (1986) Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition and cytotoxicity. J Natl Cancer Inst 76:1113

    Google Scholar 

  23. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, Shiga T (1987) Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 56:803

    Google Scholar 

  24. Taverne J, Matthews N, Depledge P, Playfair JHL (1984) Malarian parasites and tumour cells are killed by the same component of tumour necrosis serum. Clin Exp Immunol 57:293

    Google Scholar 

  25. Torti FM, Dieckmann B, Beutler B, Cerami A, Ringgold GH (1985) A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 229:867

    Google Scholar 

  26. Vilcek J, Palombella VJ, Henriksen-De Stefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M (1986) Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163:632

    Google Scholar 

  27. Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355

    Google Scholar 

  28. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ (1983) Human tumor necrosis factor produced by human B-cell lines. Synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80:5397

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Universitätsklinik und Poliklinik (Tumorforschung), West German Tumor Center, Hufelandstr. 55, D-4300, Essen 1, Federal Republic of Germany

    T. Moritz, N. Niederle, J. Baumann, D. May, E. Kurschel, R. Osieka & C. G. Schmidt

  2. Knoll AG, Knollstr. 50, D-6700, Ludwigshafen, Federal Republic of Germany

    J. Kempeni & E. Schlick

Authors
  1. T. Moritz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. May
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Kurschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Osieka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Kempeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Schlick
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. G. Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moritz, T., Niederle, N., Baumann, J. et al. Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease. Cancer Immunol Immunother 29, 144–150 (1989). https://doi.org/10.1007/BF00199290

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199290

Keywords

Search

Navigation